HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GAO Memory Supplement Review Recalls FDA's Regulatory Challenges

This article was originally published in The Rose Sheet

Executive Summary

GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.

You may also be interested in...



Yohimbe Ban Suggested, 'God' Warned: Health And Wellness Industry News

ED-spiked supplement importers identified; FDA and FTC act on GAO outreach suggestion; ephedra-like rulemaking needed for yohimbe – study; and God's book among violative claims by Florida firm.

Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA

CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.

FTC Enforcement Hangs Over Memory Product Firm After Overlooking NAD Review

KNH Online did not respond to NAD's request for information supporting claims for its Adderin supplement, including the statement "clinically proven to sky-rocket concentration by 312%" and a customer testimonial that "it started working within minutes of taking it … I experienced a mental clarity that I’d never felt before."

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS109315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel